article
Key developments: mRNA vaccines and therapeutics
EPR summarises results from key mRNA vaccine trials, highlighting the future potential of these innovative therapeutics.
List view / Grid view
The Institute of Cancer Research
news
GM herpes virus fights advanced cancers
A Phase I trial showed early potential in using a genetically engineered herpes virus to combat advanced cancers that exhibited no response to immunotherapies.
news
MHRA approves Pluvicto® and Locametz® for prostate cancer
The UK’s regulator approved Novartis’ radioligand therapy Pluvicto®▼ and radioactive diagnostic agent Locametz® for use in advanced prostate cancer.
news
Prototype AI test could predict promising cancer drug combinations
An artificial intelligence (AI)-based test was able to predict cancer patients’ response to drugs more accurately than is currently possible with genetic testing, finds proof-of-concept study.
news
Lynparza® significantly reduces risk of death in early breast cancer patients
Lynparza® (olaparib) is the first PARP inhibitor to demonstrate overall survival benefit in early breast cancer, according to new data.
news
Lynparza® improves invasive disease-free survival in high-risk early breast cancer trial
In the Phase III OlympiA trial, Lynparza® (olaparib) reduced the risk of cancer recurrences or death by 42 percent in patients with BRCA-mutated high-risk early breast cancer.
news
Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
news
Blood test predicts treatment response for metastatic prostate cancer
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy...
news
Immunotherapy drug could boost hormone treatment for prostate cancer
Researchers believe the combination with established treatment could improve outcomes in prostate cancer...
news
Scientists identify cause of resistance to breast and ovarian cancer drug
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...
news
Blood test predicts effectiveness of palbociclib in breast cancer patients
A new study has found a blood test for cancer DNA could predict if a woman is responding to the new breast cancer drug palbociclib, months earlier than current tests...
news
Scientists find genetic link between immune system and lymphoma
People who inherit genetic changes that alter the function of their immune system are at increased risk of developing Hodgkin lymphoma, according to new study by Institute of Cancer Research.
news
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
news
‘Game-changing’ immunotherapy doubles head and neck cancer survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...
news
Gene activity linked to breast cancer survival
18 August 2016 | By The Institute of Cancer Research, London
In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying...
